NRx Pharmaceuticals (NRXP) News Today $3.53 -0.48 (-11.97%) Closing price 04:00 PM EasternExtended Trading$3.52 0.00 (-0.14%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities RequirementJanuary 21 at 8:02 AM | prnewswire.comNRx Pharmaceuticals Board Member Resigns, New Member to be AppointedJanuary 16, 2025 | americanbankingnews.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.January 15, 2025 | prnewswire.comHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David FeifelJanuary 14, 2025 | investing.comHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David FeifelJanuary 14, 2025 | prnewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital MarketJanuary 13, 2025 | prnewswire.comNRx Pharmaceuticals Announces Entry into Share Purchase Agreement with HOPE Therapeutics and JGS Holdings LLCJanuary 13, 2025 | americanbankingnews.comHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago ClubJanuary 10, 2025 | finance.yahoo.comCentral Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and RegionJanuary 8, 2025 | globenewswire.comNRx Pharmaceuticals, HOPE sign term sheet for $27M in fundingJanuary 8, 2025 | markets.businessinsider.comHOPE Therapeutics announces planned acquisition of Dura MedicalJanuary 7, 2025 | markets.businessinsider.comHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San FranciscoJanuary 7, 2025 | prnewswire.comHOPE Therapeutics, NRx Pharmaceuticals Enter Into $27 Mln Financing Deal With Smith & SauerJanuary 7, 2025 | markets.businessinsider.comHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical OperationsJanuary 6, 2025 | prnewswire.comHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry ClinicsJanuary 6, 2025 | prnewswire.comNRx Pharmaceuticals, Hope announce planned acquisition of KadimaJanuary 3, 2025 | markets.businessinsider.comNRx Pharmaceuticals Stock Rises 33% on Psychiatry Clinic AcquisitionJanuary 2, 2025 | marketwatch.comNRx Pharma unit to acquire psychiatric facility KadimaJanuary 2, 2025 | msn.comHope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry ClinicsJanuary 2, 2025 | prnewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal DepressionDecember 30, 2024 | prnewswire.comInsider Buying: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Acquires 40,000 Shares of StockDecember 19, 2024 | insidertrades.comNRx Pharmaceuticals reiterates shares target with Buy rating on Q3 reportNovember 28, 2024 | uk.investing.comNRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024November 26, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"November 25, 2024 | prnewswire.comNRX Pharmaceuticals Strengthens Leadership with New CFO AppointmentNovember 20, 2024 | markets.businessinsider.comNRx Pharmaceuticals Names Michael Abrams CFONovember 20, 2024 | markets.businessinsider.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2024 Earnings Call TranscriptNovember 20, 2024 | msn.comNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial OfficerNovember 19, 2024 | finanznachrichten.deNRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ...November 19, 2024 | uk.finance.yahoo.comNRx Pharmaceuticals names Michael Abrams as CFONovember 19, 2024 | markets.businessinsider.comNRx Pharmaceuticals Reports Progress in Drug DevelopmentNovember 19, 2024 | markets.businessinsider.comNRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call TranscriptNovember 18, 2024 | seekingalpha.comNRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial OfficerNovember 18, 2024 | prnewswire.comNRX Pharmaceuticals Advances in Mental Health SectorNovember 15, 2024 | markets.businessinsider.comNRx Pharmaceuticals delays Q3 results call to November 18November 15, 2024 | uk.investing.comNRx Pharmaceuticals files to sell 3.3M shares of common stock for holdersNovember 15, 2024 | markets.businessinsider.comNRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business UpdateNovember 14, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024November 13, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024November 7, 2024 | prnewswire.comHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry ClinicsOctober 30, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024October 23, 2024 | globenewswire.comNRx Pharmaceuticals initiated with a Buy at EF HuttonOctober 22, 2024 | markets.businessinsider.comNRX Pharmaceuticals (NASDAQ:NRXP) Stock, Insider Trading ActivityOctober 16, 2024 | benzinga.comNRx Pharmaceuticals Leadership Shift and Strategic Governance DecisionsOctober 13, 2024 | finance.yahoo.comNRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100October 7, 2024 | msn.comHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric ClinicOctober 3, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)September 30, 2024 | prnewswire.comNRx Pharmaceuticals’ Innovative Treatments for Depression Gain SpotlightSeptember 16, 2024 | msn.comNRX Pharmaceuticals (NASDAQ:NRXP) Stock Quotes, Forecast and News SummarySeptember 11, 2024 | benzinga.comNRX Pharmaceuticals (NASDAQ:NRXP) Stock, Short Interest ReportSeptember 11, 2024 | benzinga.com Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address NRXP Media Mentions By Week NRXP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRXP News Sentiment▼-0.020.60▲Average Medical News Sentiment NRXP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRXP Articles This Week▼32▲NRXP Articles Average Week Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lifecore Biomedical News Heron Therapeutics News Design Therapeutics News Eledon Pharmaceuticals News COMPASS Pathways News Fulcrum Therapeutics News SOPHiA GENETICS News Larimar Therapeutics News Aurora Cannabis News 4D Molecular Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRXP) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
